nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—NTRK1—bipolar disorder	0.62	1	CbGaD
Crizotinib—TAOK2—thyroid gland—bipolar disorder	0.000853	0.00495	CbGeAlD
Crizotinib—PRKD1—cerebellum—bipolar disorder	0.000846	0.00491	CbGeAlD
Crizotinib—LIMK1—cerebellum—bipolar disorder	0.000834	0.00484	CbGeAlD
Crizotinib—EPHA3—thyroid gland—bipolar disorder	0.000821	0.00477	CbGeAlD
Crizotinib—ACVR1B—thyroid gland—bipolar disorder	0.000821	0.00477	CbGeAlD
Crizotinib—PRKD3—cerebellum—bipolar disorder	0.000813	0.00472	CbGeAlD
Crizotinib—MAPK7—nervous system—bipolar disorder	0.000798	0.00463	CbGeAlD
Crizotinib—DSTYK—cerebellum—bipolar disorder	0.000794	0.00461	CbGeAlD
Crizotinib—EPHA8—nervous system—bipolar disorder	0.00079	0.00459	CbGeAlD
Crizotinib—JAK3—thyroid gland—bipolar disorder	0.000783	0.00455	CbGeAlD
Crizotinib—DCLK1—thyroid gland—bipolar disorder	0.000779	0.00452	CbGeAlD
Crizotinib—CASK—cerebellum—bipolar disorder	0.000776	0.0045	CbGeAlD
Crizotinib—STK4—thyroid gland—bipolar disorder	0.000769	0.00446	CbGeAlD
Crizotinib—NEK9—brain—bipolar disorder	0.000754	0.00437	CbGeAlD
Crizotinib—MAPK7—cerebellum—bipolar disorder	0.000751	0.00436	CbGeAlD
Crizotinib—MET—nervous system—bipolar disorder	0.000747	0.00434	CbGeAlD
Crizotinib—TBK1—adrenal cortex—bipolar disorder	0.000744	0.00432	CbGeAlD
Crizotinib—EPHA8—cerebellum—bipolar disorder	0.000744	0.00432	CbGeAlD
Crizotinib—TYK2—adrenal cortex—bipolar disorder	0.000739	0.00429	CbGeAlD
Crizotinib—FER—thyroid gland—bipolar disorder	0.000727	0.00422	CbGeAlD
Crizotinib—CDK7—nervous system—bipolar disorder	0.000723	0.00419	CbGeAlD
Crizotinib—TNK1—thyroid gland—bipolar disorder	0.000719	0.00417	CbGeAlD
Crizotinib—RPS6KB1—adrenal cortex—bipolar disorder	0.000716	0.00415	CbGeAlD
Crizotinib—MAP4K1—thyroid gland—bipolar disorder	0.000712	0.00413	CbGeAlD
Crizotinib—BMPR1B—thyroid gland—bipolar disorder	0.000712	0.00413	CbGeAlD
Crizotinib—AXL—adrenal cortex—bipolar disorder	0.000709	0.00411	CbGeAlD
Crizotinib—MET—cerebellum—bipolar disorder	0.000703	0.00408	CbGeAlD
Crizotinib—IGF1R—thyroid gland—bipolar disorder	0.000698	0.00405	CbGeAlD
Crizotinib—TNK2—thyroid gland—bipolar disorder	0.000698	0.00405	CbGeAlD
Crizotinib—ACVR1B—nervous system—bipolar disorder	0.000691	0.00401	CbGeAlD
Crizotinib—EPHA3—nervous system—bipolar disorder	0.000691	0.00401	CbGeAlD
Crizotinib—MAP4K2—thyroid gland—bipolar disorder	0.000689	0.004	CbGeAlD
Crizotinib—PRKD1—brain—bipolar disorder	0.000687	0.00399	CbGeAlD
Crizotinib—SLK—adrenal cortex—bipolar disorder	0.000682	0.00396	CbGeAlD
Crizotinib—CDK7—cerebellum—bipolar disorder	0.00068	0.00395	CbGeAlD
Crizotinib—STK3—thyroid gland—bipolar disorder	0.000679	0.00394	CbGeAlD
Crizotinib—TIE1—thyroid gland—bipolar disorder	0.000679	0.00394	CbGeAlD
Crizotinib—LIMK1—brain—bipolar disorder	0.000678	0.00393	CbGeAlD
Crizotinib—SIK2—brain—bipolar disorder	0.000678	0.00393	CbGeAlD
Crizotinib—CYP3A4—urine—bipolar disorder	0.000678	0.00393	CbGeAlD
Crizotinib—EPHB4—adrenal cortex—bipolar disorder	0.000677	0.00393	CbGeAlD
Crizotinib—TAOK2—cerebellum—bipolar disorder	0.000675	0.00392	CbGeAlD
Crizotinib—EPHA2—adrenal cortex—bipolar disorder	0.000664	0.00386	CbGeAlD
Crizotinib—AURKA—thyroid gland—bipolar disorder	0.000662	0.00384	CbGeAlD
Crizotinib—PRKD3—brain—bipolar disorder	0.00066	0.00383	CbGeAlD
Crizotinib—EPHA6—nervous system—bipolar disorder	0.000659	0.00382	CbGeAlD
Crizotinib—JAK3—nervous system—bipolar disorder	0.000659	0.00382	CbGeAlD
Crizotinib—TESK1—thyroid gland—bipolar disorder	0.000657	0.00381	CbGeAlD
Crizotinib—DCLK1—nervous system—bipolar disorder	0.000655	0.0038	CbGeAlD
Crizotinib—ACVR1B—cerebellum—bipolar disorder	0.00065	0.00377	CbGeAlD
Crizotinib—MAP3K3—adrenal cortex—bipolar disorder	0.000648	0.00376	CbGeAlD
Crizotinib—TEK—adrenal cortex—bipolar disorder	0.000648	0.00376	CbGeAlD
Crizotinib—STK4—nervous system—bipolar disorder	0.000647	0.00375	CbGeAlD
Crizotinib—DSTYK—brain—bipolar disorder	0.000645	0.00374	CbGeAlD
Crizotinib—MERTK—thyroid gland—bipolar disorder	0.000639	0.00371	CbGeAlD
Crizotinib—LTK—brain—bipolar disorder	0.00063	0.00366	CbGeAlD
Crizotinib—CASK—brain—bipolar disorder	0.00063	0.00366	CbGeAlD
Crizotinib—LIMK2—thyroid gland—bipolar disorder	0.000625	0.00363	CbGeAlD
Crizotinib—NUAK2—thyroid gland—bipolar disorder	0.000622	0.00361	CbGeAlD
Crizotinib—JAK3—cerebellum—bipolar disorder	0.00062	0.0036	CbGeAlD
Crizotinib—MAP3K12—thyroid gland—bipolar disorder	0.000618	0.00359	CbGeAlD
Crizotinib—ACVR1—thyroid gland—bipolar disorder	0.000618	0.00359	CbGeAlD
Crizotinib—DCLK1—cerebellum—bipolar disorder	0.000616	0.00358	CbGeAlD
Crizotinib—TYRO3—nervous system—bipolar disorder	0.000611	0.00355	CbGeAlD
Crizotinib—FER—nervous system—bipolar disorder	0.000611	0.00355	CbGeAlD
Crizotinib—EPHA5—nervous system—bipolar disorder	0.000611	0.00355	CbGeAlD
Crizotinib—ALK—nervous system—bipolar disorder	0.000611	0.00355	CbGeAlD
Crizotinib—MAPK7—brain—bipolar disorder	0.00061	0.00354	CbGeAlD
Crizotinib—STK4—cerebellum—bipolar disorder	0.000609	0.00353	CbGeAlD
Crizotinib—LYN—nervous system—bipolar disorder	0.000608	0.00353	CbGeAlD
Crizotinib—STK35—thyroid gland—bipolar disorder	0.000605	0.00351	CbGeAlD
Crizotinib—EPHA8—brain—bipolar disorder	0.000604	0.00351	CbGeAlD
Crizotinib—FES—brain—bipolar disorder	0.000604	0.00351	CbGeAlD
Crizotinib—MAP3K19—nervous system—bipolar disorder	0.000599	0.00348	CbGeAlD
Crizotinib—BMPR1B—nervous system—bipolar disorder	0.000599	0.00348	CbGeAlD
Crizotinib—YES1—adrenal cortex—bipolar disorder	0.000599	0.00347	CbGeAlD
Crizotinib—TAOK3—adrenal cortex—bipolar disorder	0.000591	0.00343	CbGeAlD
Crizotinib—ABL2—thyroid gland—bipolar disorder	0.00059	0.00342	CbGeAlD
Crizotinib—IGF1R—nervous system—bipolar disorder	0.000587	0.00341	CbGeAlD
Crizotinib—TNK2—nervous system—bipolar disorder	0.000587	0.00341	CbGeAlD
Crizotinib—BMP2K—thyroid gland—bipolar disorder	0.000583	0.00338	CbGeAlD
Crizotinib—EPHA5—cerebellum—bipolar disorder	0.000575	0.00334	CbGeAlD
Crizotinib—FER—cerebellum—bipolar disorder	0.000575	0.00334	CbGeAlD
Crizotinib—TYRO3—cerebellum—bipolar disorder	0.000575	0.00334	CbGeAlD
Crizotinib—TIE1—nervous system—bipolar disorder	0.000571	0.00332	CbGeAlD
Crizotinib—MET—brain—bipolar disorder	0.000571	0.00331	CbGeAlD
Crizotinib—TNK1—cerebellum—bipolar disorder	0.000569	0.0033	CbGeAlD
Crizotinib—BMPR1B—cerebellum—bipolar disorder	0.000564	0.00327	CbGeAlD
Crizotinib—PTK2B—thyroid gland—bipolar disorder	0.000563	0.00327	CbGeAlD
Crizotinib—RIPK2—thyroid gland—bipolar disorder	0.000558	0.00324	CbGeAlD
Crizotinib—AURKA—nervous system—bipolar disorder	0.000557	0.00323	CbGeAlD
Crizotinib—TNK2—cerebellum—bipolar disorder	0.000553	0.00321	CbGeAlD
Crizotinib—IGF1R—cerebellum—bipolar disorder	0.000553	0.00321	CbGeAlD
Crizotinib—CDK7—brain—bipolar disorder	0.000552	0.00321	CbGeAlD
Crizotinib—TESK1—nervous system—bipolar disorder	0.000552	0.0032	CbGeAlD
Crizotinib—TAOK2—brain—bipolar disorder	0.000548	0.00318	CbGeAlD
Crizotinib—MAP4K2—cerebellum—bipolar disorder	0.000545	0.00316	CbGeAlD
Crizotinib—EPHA4—thyroid gland—bipolar disorder	0.00054	0.00313	CbGeAlD
Crizotinib—STK3—cerebellum—bipolar disorder	0.000538	0.00312	CbGeAlD
Crizotinib—TIE1—cerebellum—bipolar disorder	0.000538	0.00312	CbGeAlD
Crizotinib—MERTK—nervous system—bipolar disorder	0.000537	0.00312	CbGeAlD
Crizotinib—MAP3K2—thyroid gland—bipolar disorder	0.000529	0.00307	CbGeAlD
Crizotinib—EPHA3—brain—bipolar disorder	0.000528	0.00306	CbGeAlD
Crizotinib—ACVR1B—brain—bipolar disorder	0.000528	0.00306	CbGeAlD
Crizotinib—LIMK2—nervous system—bipolar disorder	0.000525	0.00305	CbGeAlD
Crizotinib—ACVR1—nervous system—bipolar disorder	0.00052	0.00302	CbGeAlD
Crizotinib—MAP3K12—nervous system—bipolar disorder	0.00052	0.00302	CbGeAlD
Crizotinib—TESK1—cerebellum—bipolar disorder	0.00052	0.00302	CbGeAlD
Crizotinib—PTK2—thyroid gland—bipolar disorder	0.000518	0.00301	CbGeAlD
Crizotinib—TBK1—thyroid gland—bipolar disorder	0.000518	0.00301	CbGeAlD
Crizotinib—CSF1R—adrenal cortex—bipolar disorder	0.000517	0.003	CbGeAlD
Crizotinib—TYK2—thyroid gland—bipolar disorder	0.000515	0.00299	CbGeAlD
Crizotinib—STK35—nervous system—bipolar disorder	0.000509	0.00296	CbGeAlD
Crizotinib—IRAK1—thyroid gland—bipolar disorder	0.000508	0.00295	CbGeAlD
Crizotinib—MERTK—cerebellum—bipolar disorder	0.000506	0.00293	CbGeAlD
Crizotinib—JAK3—brain—bipolar disorder	0.000504	0.00292	CbGeAlD
Crizotinib—EPHA6—brain—bipolar disorder	0.000504	0.00292	CbGeAlD
Crizotinib—DCLK1—brain—bipolar disorder	0.000501	0.0029	CbGeAlD
Crizotinib—RPS6KB1—thyroid gland—bipolar disorder	0.000499	0.00289	CbGeAlD
Crizotinib—PLK4—brain—bipolar disorder	0.000497	0.00289	CbGeAlD
Crizotinib—FGR—thyroid gland—bipolar disorder	0.000496	0.00288	CbGeAlD
Crizotinib—LCK—thyroid gland—bipolar disorder	0.000496	0.00288	CbGeAlD
Crizotinib—STK4—brain—bipolar disorder	0.000494	0.00287	CbGeAlD
Crizotinib—LIMK2—cerebellum—bipolar disorder	0.000494	0.00287	CbGeAlD
Crizotinib—AXL—thyroid gland—bipolar disorder	0.000494	0.00286	CbGeAlD
Crizotinib—NUAK2—cerebellum—bipolar disorder	0.000493	0.00286	CbGeAlD
Crizotinib—BMP2K—nervous system—bipolar disorder	0.00049	0.00284	CbGeAlD
Crizotinib—FLT3—cerebellum—bipolar disorder	0.000489	0.00284	CbGeAlD
Crizotinib—MAP3K12—cerebellum—bipolar disorder	0.000489	0.00284	CbGeAlD
Crizotinib—ACVR1—cerebellum—bipolar disorder	0.000489	0.00284	CbGeAlD
Crizotinib—STK35—cerebellum—bipolar disorder	0.000479	0.00278	CbGeAlD
Crizotinib—SLK—thyroid gland—bipolar disorder	0.000475	0.00276	CbGeAlD
Crizotinib—PTK2B—nervous system—bipolar disorder	0.000473	0.00275	CbGeAlD
Crizotinib—EPHB4—thyroid gland—bipolar disorder	0.000472	0.00274	CbGeAlD
Crizotinib—CYP3A5—blood plasma—bipolar disorder	0.000471	0.00273	CbGeAlD
Crizotinib—JAK2—thyroid gland—bipolar disorder	0.000468	0.00272	CbGeAlD
Crizotinib—EPHA5—brain—bipolar disorder	0.000467	0.00271	CbGeAlD
Crizotinib—ALK—brain—bipolar disorder	0.000467	0.00271	CbGeAlD
Crizotinib—TYRO3—brain—bipolar disorder	0.000467	0.00271	CbGeAlD
Crizotinib—FER—brain—bipolar disorder	0.000467	0.00271	CbGeAlD
Crizotinib—ABL2—cerebellum—bipolar disorder	0.000467	0.00271	CbGeAlD
Crizotinib—LYN—brain—bipolar disorder	0.000465	0.0027	CbGeAlD
Crizotinib—EPHA2—thyroid gland—bipolar disorder	0.000463	0.00269	CbGeAlD
Crizotinib—TNK1—brain—bipolar disorder	0.000462	0.00268	CbGeAlD
Crizotinib—BMP2K—cerebellum—bipolar disorder	0.000461	0.00268	CbGeAlD
Crizotinib—MAP4K1—brain—bipolar disorder	0.000458	0.00266	CbGeAlD
Crizotinib—BMPR1B—brain—bipolar disorder	0.000458	0.00266	CbGeAlD
Crizotinib—MAP3K19—brain—bipolar disorder	0.000458	0.00266	CbGeAlD
Crizotinib—EPHA4—nervous system—bipolar disorder	0.000454	0.00263	CbGeAlD
Crizotinib—MAP4K5—thyroid gland—bipolar disorder	0.000451	0.00262	CbGeAlD
Crizotinib—TEK—thyroid gland—bipolar disorder	0.000451	0.00262	CbGeAlD
Crizotinib—MAP3K3—thyroid gland—bipolar disorder	0.000451	0.00262	CbGeAlD
Crizotinib—TNK2—brain—bipolar disorder	0.000449	0.00261	CbGeAlD
Crizotinib—IGF1R—brain—bipolar disorder	0.000449	0.00261	CbGeAlD
Crizotinib—PTK2B—cerebellum—bipolar disorder	0.000446	0.00259	CbGeAlD
Crizotinib—MAP3K2—nervous system—bipolar disorder	0.000445	0.00258	CbGeAlD
Crizotinib—MAP4K2—brain—bipolar disorder	0.000443	0.00257	CbGeAlD
Crizotinib—RIPK2—cerebellum—bipolar disorder	0.000442	0.00256	CbGeAlD
Crizotinib—STK3—brain—bipolar disorder	0.000437	0.00253	CbGeAlD
Crizotinib—TIE1—brain—bipolar disorder	0.000437	0.00253	CbGeAlD
Crizotinib—PTK2—nervous system—bipolar disorder	0.000436	0.00253	CbGeAlD
Crizotinib—TBK1—nervous system—bipolar disorder	0.000436	0.00253	CbGeAlD
Crizotinib—TYK2—nervous system—bipolar disorder	0.000433	0.00251	CbGeAlD
Crizotinib—EPHB6—thyroid gland—bipolar disorder	0.000431	0.0025	CbGeAlD
Crizotinib—EPHA4—cerebellum—bipolar disorder	0.000427	0.00248	CbGeAlD
Crizotinib—AURKA—brain—bipolar disorder	0.000426	0.00247	CbGeAlD
Crizotinib—TESK1—brain—bipolar disorder	0.000422	0.00245	CbGeAlD
Crizotinib—RPS6KB1—nervous system—bipolar disorder	0.000419	0.00243	CbGeAlD
Crizotinib—MAP3K2—cerebellum—bipolar disorder	0.000419	0.00243	CbGeAlD
Crizotinib—YES1—thyroid gland—bipolar disorder	0.000417	0.00242	CbGeAlD
Crizotinib—FGR—nervous system—bipolar disorder	0.000417	0.00242	CbGeAlD
Crizotinib—AXL—nervous system—bipolar disorder	0.000415	0.00241	CbGeAlD
Crizotinib—STK10—thyroid gland—bipolar disorder	0.000413	0.0024	CbGeAlD
Crizotinib—TAOK3—thyroid gland—bipolar disorder	0.000412	0.00239	CbGeAlD
Crizotinib—MERTK—brain—bipolar disorder	0.000411	0.00238	CbGeAlD
Crizotinib—PTK2—cerebellum—bipolar disorder	0.00041	0.00238	CbGeAlD
Crizotinib—TBK1—cerebellum—bipolar disorder	0.00041	0.00238	CbGeAlD
Crizotinib—ABL1—adrenal cortex—bipolar disorder	0.000409	0.00237	CbGeAlD
Crizotinib—TYK2—cerebellum—bipolar disorder	0.000407	0.00236	CbGeAlD
Crizotinib—IRAK1—cerebellum—bipolar disorder	0.000402	0.00233	CbGeAlD
Crizotinib—LIMK2—brain—bipolar disorder	0.000402	0.00233	CbGeAlD
Crizotinib—SRC—thyroid gland—bipolar disorder	0.000401	0.00233	CbGeAlD
Crizotinib—NUAK2—brain—bipolar disorder	0.0004	0.00232	CbGeAlD
Crizotinib—MAP3K12—brain—bipolar disorder	0.000397	0.00231	CbGeAlD
Crizotinib—ACVR1—brain—bipolar disorder	0.000397	0.00231	CbGeAlD
Crizotinib—RPS6KB1—cerebellum—bipolar disorder	0.000395	0.00229	CbGeAlD
Crizotinib—JAK2—nervous system—bipolar disorder	0.000394	0.00229	CbGeAlD
Crizotinib—AXL—cerebellum—bipolar disorder	0.000391	0.00227	CbGeAlD
Crizotinib—STK35—brain—bipolar disorder	0.000389	0.00226	CbGeAlD
Crizotinib—EPHA2—nervous system—bipolar disorder	0.000389	0.00226	CbGeAlD
Crizotinib—MAP4K5—nervous system—bipolar disorder	0.00038	0.0022	CbGeAlD
Crizotinib—MAP3K3—nervous system—bipolar disorder	0.00038	0.0022	CbGeAlD
Crizotinib—TEK—nervous system—bipolar disorder	0.00038	0.0022	CbGeAlD
Crizotinib—ABL2—brain—bipolar disorder	0.000379	0.0022	CbGeAlD
Crizotinib—SLK—cerebellum—bipolar disorder	0.000376	0.00218	CbGeAlD
Crizotinib—BMP2K—brain—bipolar disorder	0.000375	0.00217	CbGeAlD
Crizotinib—EPHB4—cerebellum—bipolar disorder	0.000373	0.00217	CbGeAlD
Crizotinib—JAK2—cerebellum—bipolar disorder	0.000371	0.00215	CbGeAlD
Crizotinib—EPHB6—nervous system—bipolar disorder	0.000363	0.00211	CbGeAlD
Crizotinib—PTK2B—brain—bipolar disorder	0.000362	0.0021	CbGeAlD
Crizotinib—CSF1R—thyroid gland—bipolar disorder	0.00036	0.00209	CbGeAlD
Crizotinib—RIPK2—brain—bipolar disorder	0.000359	0.00208	CbGeAlD
Crizotinib—TEK—cerebellum—bipolar disorder	0.000357	0.00207	CbGeAlD
Crizotinib—MAP3K3—cerebellum—bipolar disorder	0.000357	0.00207	CbGeAlD
Crizotinib—MAP4K5—cerebellum—bipolar disorder	0.000357	0.00207	CbGeAlD
Crizotinib—CYP3A4—blood plasma—bipolar disorder	0.000354	0.00205	CbGeAlD
Crizotinib—YES1—nervous system—bipolar disorder	0.000351	0.00204	CbGeAlD
Crizotinib—STK10—nervous system—bipolar disorder	0.000348	0.00202	CbGeAlD
Crizotinib—EPHA4—brain—bipolar disorder	0.000347	0.00201	CbGeAlD
Crizotinib—TAOK3—nervous system—bipolar disorder	0.000346	0.00201	CbGeAlD
Crizotinib—EPHB6—cerebellum—bipolar disorder	0.000341	0.00198	CbGeAlD
Crizotinib—MAP3K2—brain—bipolar disorder	0.00034	0.00197	CbGeAlD
Crizotinib—SRC—nervous system—bipolar disorder	0.000337	0.00196	CbGeAlD
Crizotinib—TBK1—brain—bipolar disorder	0.000333	0.00193	CbGeAlD
Crizotinib—PTK2—brain—bipolar disorder	0.000333	0.00193	CbGeAlD
Crizotinib—TYK2—brain—bipolar disorder	0.000331	0.00192	CbGeAlD
Crizotinib—YES1—cerebellum—bipolar disorder	0.00033	0.00191	CbGeAlD
Crizotinib—STK10—cerebellum—bipolar disorder	0.000327	0.0019	CbGeAlD
Crizotinib—IRAK1—brain—bipolar disorder	0.000327	0.0019	CbGeAlD
Crizotinib—TAOK3—cerebellum—bipolar disorder	0.000326	0.00189	CbGeAlD
Crizotinib—RPS6KB1—brain—bipolar disorder	0.000321	0.00186	CbGeAlD
Crizotinib—FGR—brain—bipolar disorder	0.000319	0.00185	CbGeAlD
Crizotinib—SRC—cerebellum—bipolar disorder	0.000317	0.00184	CbGeAlD
Crizotinib—AXL—brain—bipolar disorder	0.000317	0.00184	CbGeAlD
Crizotinib—SLK—brain—bipolar disorder	0.000305	0.00177	CbGeAlD
Crizotinib—EPHB4—brain—bipolar disorder	0.000303	0.00176	CbGeAlD
Crizotinib—CSF1R—nervous system—bipolar disorder	0.000303	0.00176	CbGeAlD
Crizotinib—JAK2—brain—bipolar disorder	0.000301	0.00175	CbGeAlD
Crizotinib—EPHA2—brain—bipolar disorder	0.000297	0.00173	CbGeAlD
Crizotinib—MAP4K5—brain—bipolar disorder	0.00029	0.00168	CbGeAlD
Crizotinib—MAP3K3—brain—bipolar disorder	0.00029	0.00168	CbGeAlD
Crizotinib—TEK—brain—bipolar disorder	0.00029	0.00168	CbGeAlD
Crizotinib—CSF1R—cerebellum—bipolar disorder	0.000285	0.00165	CbGeAlD
Crizotinib—ABL1—thyroid gland—bipolar disorder	0.000285	0.00165	CbGeAlD
Crizotinib—EPHB6—brain—bipolar disorder	0.000277	0.00161	CbGeAlD
Crizotinib—YES1—brain—bipolar disorder	0.000268	0.00156	CbGeAlD
Crizotinib—STK10—brain—bipolar disorder	0.000266	0.00154	CbGeAlD
Crizotinib—TAOK3—brain—bipolar disorder	0.000265	0.00154	CbGeAlD
Crizotinib—SRC—brain—bipolar disorder	0.000258	0.0015	CbGeAlD
Crizotinib—ABCB1—blood plasma—bipolar disorder	0.00025	0.00145	CbGeAlD
Crizotinib—ABL1—nervous system—bipolar disorder	0.000239	0.00139	CbGeAlD
Crizotinib—CSF1R—brain—bipolar disorder	0.000231	0.00134	CbGeAlD
Crizotinib—ABL1—cerebellum—bipolar disorder	0.000225	0.00131	CbGeAlD
Crizotinib—ABL1—brain—bipolar disorder	0.000183	0.00106	CbGeAlD
Crizotinib—ABCB1—adrenal cortex—bipolar disorder	0.000127	0.000737	CbGeAlD
Crizotinib—CYP3A4—nervous system—bipolar disorder	0.000105	0.00061	CbGeAlD
Crizotinib—ABCB1—thyroid gland—bipolar disorder	8.85e-05	0.000514	CbGeAlD
Crizotinib—ABCB1—nervous system—bipolar disorder	7.44e-05	0.000432	CbGeAlD
Crizotinib—ABCB1—cerebellum—bipolar disorder	7.01e-05	0.000407	CbGeAlD
Crizotinib—ABCB1—brain—bipolar disorder	5.69e-05	0.00033	CbGeAlD
Crizotinib—TYK2—Signaling Pathways—TCF7L2—bipolar disorder	8.82e-06	4.24e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKR1C4—bipolar disorder	8.77e-06	4.21e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—GSK3A—bipolar disorder	8.76e-06	4.21e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—DRD2—bipolar disorder	8.75e-06	4.21e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—MTHFR—bipolar disorder	8.74e-06	4.2e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NTRK1—bipolar disorder	8.73e-06	4.19e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NRG1—bipolar disorder	8.73e-06	4.19e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—GSK3B—bipolar disorder	8.72e-06	4.19e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—GSK3B—bipolar disorder	8.7e-06	4.18e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—HTR2A—bipolar disorder	8.66e-06	4.16e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NTRK1—bipolar disorder	8.61e-06	4.14e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HTR2A—bipolar disorder	8.61e-06	4.13e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—INS—bipolar disorder	8.6e-06	4.13e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—NRG1—bipolar disorder	8.52e-06	4.09e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ADM—bipolar disorder	8.52e-06	4.09e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—S100B—bipolar disorder	8.49e-06	4.08e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HTR2A—bipolar disorder	8.48e-06	4.07e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NRG1—bipolar disorder	8.48e-06	4.07e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—GSK3B—bipolar disorder	8.41e-06	4.04e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-E—bipolar disorder	8.41e-06	4.04e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—SNAP25—bipolar disorder	8.39e-06	4.03e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—ADCY2—bipolar disorder	8.39e-06	4.03e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HTR1A—bipolar disorder	8.38e-06	4.03e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—S100B—bipolar disorder	8.37e-06	4.02e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—GSK3B—bipolar disorder	8.36e-06	4.01e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TCF7L2—bipolar disorder	8.36e-06	4.01e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TSHB—bipolar disorder	8.3e-06	3.99e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PDE4B—bipolar disorder	8.3e-06	3.99e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TACR1—bipolar disorder	8.3e-06	3.99e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—GSK3B—bipolar disorder	8.29e-06	3.98e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—POMC—bipolar disorder	8.29e-06	3.98e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TAC1—bipolar disorder	8.25e-06	3.97e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NTRK1—bipolar disorder	8.17e-06	3.92e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HTR2A—bipolar disorder	8.12e-06	3.9e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD1—bipolar disorder	8.09e-06	3.89e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HTR2C—bipolar disorder	8.09e-06	3.89e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—GSK3A—bipolar disorder	8.09e-06	3.89e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ADCY2—bipolar disorder	8.04e-06	3.86e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NRG1—bipolar disorder	7.97e-06	3.83e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—S100B—bipolar disorder	7.94e-06	3.81e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NTRK1—bipolar disorder	7.93e-06	3.81e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—S100B—bipolar disorder	7.91e-06	3.8e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—bipolar disorder	7.91e-06	3.8e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TRPC3—bipolar disorder	7.9e-06	3.8e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL1B—bipolar disorder	7.89e-06	3.79e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NTRK2—bipolar disorder	7.87e-06	3.78e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NR1D1—bipolar disorder	7.87e-06	3.78e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HTR2A—bipolar disorder	7.87e-06	3.78e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HTR2A—bipolar disorder	7.87e-06	3.78e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—GSK3B—bipolar disorder	7.87e-06	3.78e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—ADCY2—bipolar disorder	7.85e-06	3.77e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HTR1A—bipolar disorder	7.84e-06	3.77e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD3—bipolar disorder	7.84e-06	3.77e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—GSK3A—bipolar disorder	7.81e-06	3.75e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL1B—bipolar disorder	7.77e-06	3.74e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—GSK3B—bipolar disorder	7.77e-06	3.73e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TAC1—bipolar disorder	7.72e-06	3.71e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—POMC—bipolar disorder	7.71e-06	3.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—S100B—bipolar disorder	7.71e-06	3.7e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—GSK3B—bipolar disorder	7.7e-06	3.7e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—INS—bipolar disorder	7.67e-06	3.68e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—GSK3B—bipolar disorder	7.64e-06	3.67e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD4—bipolar disorder	7.61e-06	3.66e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL1B—bipolar disorder	7.59e-06	3.65e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HTR2C—bipolar disorder	7.58e-06	3.64e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD1—bipolar disorder	7.58e-06	3.64e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL1B—bipolar disorder	7.56e-06	3.63e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ADM—bipolar disorder	7.54e-06	3.62e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NCAN—bipolar disorder	7.53e-06	3.62e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NRG1—bipolar disorder	7.49e-06	3.6e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ADCY2—bipolar disorder	7.42e-06	3.57e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—GSK3B—bipolar disorder	7.4e-06	3.55e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—TCF7L2—bipolar disorder	7.4e-06	3.55e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NRG1—bipolar disorder	7.39e-06	3.55e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC5A3—bipolar disorder	7.38e-06	3.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NTRK2—bipolar disorder	7.37e-06	3.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NRG1—bipolar disorder	7.36e-06	3.54e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TSHB—bipolar disorder	7.35e-06	3.53e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PDE4B—bipolar disorder	7.35e-06	3.53e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TACR1—bipolar disorder	7.35e-06	3.53e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD3—bipolar disorder	7.34e-06	3.52e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Biological oxidations—POMC—bipolar disorder	7.34e-06	3.52e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—GSK3A—bipolar disorder	7.3e-06	3.51e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ADCY2—bipolar disorder	7.16e-06	3.44e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TCF7L2—bipolar disorder	7.14e-06	3.43e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD4—bipolar disorder	7.12e-06	3.42e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD2—bipolar disorder	7.09e-06	3.41e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CLOCK—bipolar disorder	7.07e-06	3.4e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—GSK3B—bipolar disorder	7.05e-06	3.39e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NRG1—bipolar disorder	7.01e-06	3.37e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—S100B—bipolar disorder	7e-06	3.36e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NRG1—bipolar disorder	6.98e-06	3.35e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—INS—bipolar disorder	6.95e-06	3.34e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—GSK3B—bipolar disorder	6.93e-06	3.33e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—POMC—bipolar disorder	6.92e-06	3.32e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TPH2—bipolar disorder	6.89e-06	3.31e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TSHB—bipolar disorder	6.89e-06	3.31e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CACNB2—bipolar disorder	6.89e-06	3.31e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—POMC—bipolar disorder	6.87e-06	3.3e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR1A—bipolar disorder	6.87e-06	3.3e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—INS—bipolar disorder	6.83e-06	3.28e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—GSK3B—bipolar disorder	6.83e-06	3.28e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRG1—bipolar disorder	6.8e-06	3.27e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—DPYD—bipolar disorder	6.78e-06	3.26e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—POMC—bipolar disorder	6.77e-06	3.25e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TAC1—bipolar disorder	6.77e-06	3.25e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HTR2A—bipolar disorder	6.75e-06	3.24e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—INS—bipolar disorder	6.74e-06	3.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ADCY2—bipolar disorder	6.7e-06	3.22e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TCF7L2—bipolar disorder	6.68e-06	3.21e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HTR2A—bipolar disorder	6.66e-06	3.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD2—bipolar disorder	6.64e-06	3.19e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR2C—bipolar disorder	6.64e-06	3.19e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD1—bipolar disorder	6.64e-06	3.19e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MTHFR—bipolar disorder	6.63e-06	3.18e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—IMPA1—bipolar disorder	6.56e-06	3.15e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—GSK3B—bipolar disorder	6.54e-06	3.14e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—POMC—bipolar disorder	6.48e-06	3.11e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NTRK2—bipolar disorder	6.45e-06	3.1e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—INS—bipolar disorder	6.45e-06	3.1e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NRG1—bipolar disorder	6.45e-06	3.1e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD3—bipolar disorder	6.43e-06	3.09e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NTRK1—bipolar disorder	6.42e-06	3.08e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—GSK3A—bipolar disorder	6.4e-06	3.07e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—GSK3B—bipolar disorder	6.34e-06	3.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HTR2A—bipolar disorder	6.32e-06	3.03e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CACNA1C—bipolar disorder	6.3e-06	3.03e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—POMC—bipolar disorder	6.29e-06	3.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—POMC—bipolar disorder	6.28e-06	3.02e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—INS—bipolar disorder	6.25e-06	3e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—S100B—bipolar disorder	6.24e-06	3e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD4—bipolar disorder	6.24e-06	3e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL1B—bipolar disorder	6.19e-06	2.97e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—GSK3B—bipolar disorder	6.18e-06	2.97e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRG1—bipolar disorder	6.18e-06	2.97e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—GSK3B—bipolar disorder	6.15e-06	2.96e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3C2A—bipolar disorder	6.14e-06	2.95e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HTR2A—bipolar disorder	6.13e-06	2.95e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL1B—bipolar disorder	6.1e-06	2.93e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR1A—bipolar disorder	6.08e-06	2.92e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NTRK1—bipolar disorder	6.01e-06	2.89e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TAC1—bipolar disorder	5.99e-06	2.88e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR2C—bipolar disorder	5.87e-06	2.82e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD1—bipolar disorder	5.87e-06	2.82e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ADCY2—bipolar disorder	5.87e-06	2.82e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TCF7L2—bipolar disorder	5.85e-06	2.81e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—S100B—bipolar disorder	5.84e-06	2.81e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD2—bipolar disorder	5.81e-06	2.79e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MTHFR—bipolar disorder	5.8e-06	2.79e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL1B—bipolar disorder	5.79e-06	2.78e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—GSK3B—bipolar disorder	5.79e-06	2.78e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NTRK2—bipolar disorder	5.71e-06	2.75e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NRG1—bipolar disorder	5.71e-06	2.74e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD3—bipolar disorder	5.69e-06	2.73e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GSK3A—bipolar disorder	5.66e-06	2.72e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL1B—bipolar disorder	5.62e-06	2.7e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NDUFV2—bipolar disorder	5.58e-06	2.68e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD4—bipolar disorder	5.52e-06	2.65e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—SNAP25—bipolar disorder	5.51e-06	2.65e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRG1—bipolar disorder	5.51e-06	2.65e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—GSK3B—bipolar disorder	5.44e-06	2.61e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKR1C4—bipolar disorder	5.4e-06	2.59e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—POMC—bipolar disorder	5.39e-06	2.59e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—INS—bipolar disorder	5.36e-06	2.58e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—GSK3B—bipolar disorder	5.36e-06	2.58e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—GSK3B—bipolar disorder	5.34e-06	2.57e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CLOCK—bipolar disorder	5.33e-06	2.56e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—POMC—bipolar disorder	5.32e-06	2.56e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—INS—bipolar disorder	5.29e-06	2.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—INS—bipolar disorder	5.27e-06	2.53e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NTRK1—bipolar disorder	5.26e-06	2.53e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TSHB—bipolar disorder	5.2e-06	2.5e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TPH2—bipolar disorder	5.2e-06	2.5e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CACNB2—bipolar disorder	5.2e-06	2.5e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ADCY2—bipolar disorder	5.2e-06	2.5e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TCF7L2—bipolar disorder	5.18e-06	2.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRG1—bipolar disorder	5.15e-06	2.48e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD2—bipolar disorder	5.14e-06	2.47e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MTHFR—bipolar disorder	5.14e-06	2.47e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—S100B—bipolar disorder	5.11e-06	2.46e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—DPYD—bipolar disorder	5.11e-06	2.46e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—GSK3B—bipolar disorder	5.09e-06	2.44e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—GSK3B—bipolar disorder	5.07e-06	2.44e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—POMC—bipolar disorder	5.04e-06	2.42e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—INS—bipolar disorder	5.02e-06	2.41e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HTR2A—bipolar disorder	4.97e-06	2.39e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—GSK3B—bipolar disorder	4.94e-06	2.37e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—POMC—bipolar disorder	4.9e-06	2.35e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ADCY2—bipolar disorder	4.87e-06	2.34e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—INS—bipolar disorder	4.87e-06	2.34e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NR1D1—bipolar disorder	4.85e-06	2.33e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CACNA1C—bipolar disorder	4.75e-06	2.28e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—GSK3B—bipolar disorder	4.68e-06	2.25e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NTRK1—bipolar disorder	4.66e-06	2.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HTR2A—bipolar disorder	4.65e-06	2.23e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCAN—bipolar disorder	4.64e-06	2.23e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3C2A—bipolar disorder	4.63e-06	2.23e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—INS—bipolar disorder	4.62e-06	2.22e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1B—bipolar disorder	4.55e-06	2.19e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC5A3—bipolar disorder	4.55e-06	2.18e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1B—bipolar disorder	4.53e-06	2.18e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—S100B—bipolar disorder	4.53e-06	2.18e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRG1—bipolar disorder	4.51e-06	2.17e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—GSK3B—bipolar disorder	4.49e-06	2.16e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—bipolar disorder	4.26e-06	2.05e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—COMT—bipolar disorder	4.17e-06	2.01e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SNAP25—bipolar disorder	4.16e-06	2e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MAOA—bipolar disorder	4.14e-06	1.99e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—GSK3B—bipolar disorder	4.14e-06	1.99e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—INS—bipolar disorder	4.09e-06	1.96e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR2A—bipolar disorder	4.07e-06	1.96e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—GSK3B—bipolar disorder	4e-06	1.92e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRG1—bipolar disorder	4e-06	1.92e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—POMC—bipolar disorder	3.97e-06	1.91e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—INS—bipolar disorder	3.94e-06	1.89e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—GSK3B—bipolar disorder	3.74e-06	1.8e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—bipolar disorder	3.73e-06	1.79e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—POMC—bipolar disorder	3.71e-06	1.78e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—INS—bipolar disorder	3.69e-06	1.77e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ADCY2—bipolar disorder	3.68e-06	1.77e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR2A—bipolar disorder	3.6e-06	1.73e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—bipolar disorder	3.37e-06	1.62e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—bipolar disorder	3.3e-06	1.59e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CLOCK—bipolar disorder	3.29e-06	1.58e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—GSK3B—bipolar disorder	3.28e-06	1.57e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—bipolar disorder	3.25e-06	1.56e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—INS—bipolar disorder	3.23e-06	1.55e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TPH2—bipolar disorder	3.2e-06	1.54e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CACNB2—bipolar disorder	3.2e-06	1.54e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TSHB—bipolar disorder	3.2e-06	1.54e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—DPYD—bipolar disorder	3.15e-06	1.51e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—COMT—bipolar disorder	3.15e-06	1.51e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MAOA—bipolar disorder	3.13e-06	1.5e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CACNA1C—bipolar disorder	2.93e-06	1.41e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GSK3B—bipolar disorder	2.9e-06	1.39e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—bipolar disorder	2.88e-06	1.38e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—INS—bipolar disorder	2.86e-06	1.37e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3C2A—bipolar disorder	2.85e-06	1.37e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—bipolar disorder	2.7e-06	1.3e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—INS—bipolar disorder	2.68e-06	1.29e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SNAP25—bipolar disorder	2.56e-06	1.23e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—bipolar disorder	2.55e-06	1.22e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADCY2—bipolar disorder	2.27e-06	1.09e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—bipolar disorder	2.04e-06	9.78e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—INS—bipolar disorder	2.02e-06	9.73e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—COMT—bipolar disorder	1.94e-06	9.32e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MAOA—bipolar disorder	1.93e-06	9.26e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—bipolar disorder	1.57e-06	7.54e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—bipolar disorder	1.25e-06	6.03e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—INS—bipolar disorder	1.25e-06	5.99e-06	CbGpPWpGaD
